|
Aug 28, 2008
|
Affymax Announces Upcoming Webcasts and Conference Participation
|
6.1 KB |
|
| |
PALO ALTO, Calif., Aug 28, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the Company's participation at the following investor conferences during the month of September.
Thomas Weisel Partners Healthcare Conference 2008
Four Seasons Hotel, Boston
September 3
8:35 a.m. Eastern Time
BioCentury Newsmakers in the Biotech I...
|
|
Aug 18, 2008
|
Affymax(R) Reports Second Quarter 2008 Financial Results
|
10.9 KB |
|
| |
PALO ALTO, Calif., Aug 18, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2008. The net loss for the second quarter of 2008 was $18.9 million compared to a net loss of $9.2 million for the second quarter of 2007.
Affymax recognized revenue for the quarter ended June 30,...
|
|
Aug 7, 2008
|
Affymax Announces Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
|
8.5 KB |
|
| |
PALO ALTO, Calif., Aug 07, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed its first review of the data and informed the company that the cumulative safety data generated thus far from the EMERAL...
|
|
Jul 28, 2008
|
Affymax Announces Upcoming Webcasts and Conference Participation
|
6.0 KB |
|
| |
PALO ALTO, Calif., Jul 28, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the Company's participation at the following investor conferences in August.
Arlene Morris, president and chief executive officer, will present at
BMO Capital Markets Focus on Healthcare 2008 Investor Conference
Millennium Broadway Hotel, New Yor...
|
|
Jul 9, 2008
|
Affymax Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
|
9.5 KB |
|
| |
PALO ALTO, Calif., Jul 09, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hemat...
|
|
Jun 30, 2008
|
Affymax Initiates Clinical Trial of Hematide(TM) to Evaluate Correction of Anemia in Chronic Renal Failure Patients on Dialysis
|
8.1 KB |
|
| |
PALO ALTO, Calif., Jun 30, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA). The trial i...
|
|
Jun 4, 2008
|
Affymax(R) Announces Executive Management Promotions
|
7.3 KB |
|
| |
PALO ALTO, Calif., Jun 04, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the promotions of Robert F. Venteicher, Ph.D. to senior vice president, Technical Operations and Grace U. Shin, J.D., to general counsel.
"I am pleased to recognize the significant and important contributions that both Bob and Grace have made in the g...
|
|
May 12, 2008
|
Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
|
13.9 KB |
|
| |
STOCKHOLM, Sweden, May 12, 2008 (BUSINESS WIRE) -- Takeda Global Research & Development Center, Inc. and Affymax, Inc. (Nasdaq:AFFY) today reported positive 12 month data from their ongoing Phase 2 trial(1) evaluating the safety and tolerability of Hematide(TM), an investigational drug in development for the treatment of anemia associated with chro...
|
|
May 9, 2008
|
Affymax(R) Reports First Quarter 2008 Financial Results
|
10.5 KB |
|
| |
PALO ALTO, Calif., May 09, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the first quarter ended March 31, 2008. The net loss for the first quarter of 2008 was $15.6 million compared to a net loss of $7.2 million for the first quarter of 2007.
Affymax recognized revenue for the quarter ended March 31, ...
|
|
Apr 22, 2008
|
Affymax Announces Upcoming Webcasts and Conference Participation
|
6.0 KB |
|
| |
PALO ALTO, Calif., Apr 22, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the following investor conferences in April and May.
Morgan Stanley Global Healthcare Unplugged Conference
The Ritz-Carlton, Key Biscayne, Fla.
Wednesday, Apr...
|
|
Apr 14, 2008
|
Affymax Appoints Vice President, Biostatistics and Data Management
|
6.9 KB |
|
| |
PALO ALTO, Calif., Apr 14, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Carol Francisco, Ph.D. as vice president, Biostatistics and Data Management. Dr. Francisco, who has more than 20 years of biostatistics and data management experience, joins Affymax as a member of the senior management team reporting to...
|
|
Apr 4, 2008
|
Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
|
9.2 KB |
|
| |
DALLAS, Apr 04, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development today announced data from their ongoing Phase 2 trial to assess the long-term safety and tolerability of Hematide(TM), a potential treatment of anemia. These data showed that Hematide, dosed once every four weeks, successfully maintained mea...
|
|
Mar 13, 2008
|
Affymax(R) Reports Year End 2007 Financial Results
|
11.4 KB |
|
| |
PALO ALTO, Calif., Mar 13, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the year ended December 31, 2007. The net loss for the year 2007 was $43.1 million compared to a net loss of $48.3 million for the year ended December 31, 2006.
Affymax recognized revenue for the year ended December 31, 2007 of $4...
|
|
Mar 10, 2008
|
Affymax to Present at Cowen and Company's 28th Annual Health Care Conference
|
5.8 KB |
|
| |
PALO ALTO, Calif., Mar 10, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Jeffrey H. Knapp, the company's chief commercial officer, will present at Cowen and Company's 28th Annual Health Care Conference on Monday, March 17, 2008, at 11:30 a.m. ET at The Boston Marriott Copley Place.
A live webcast of the presentation w...
|
|
Feb 5, 2008
|
Affymax Affirms Progress with Takeda Collaboration
|
6.8 KB |
|
| |
PALO ALTO, Calif., Feb 05, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today affirmed its ongoing collaboration with Takeda Pharmaceutical Company Limited for the global development and commercialization of Hematide(TM), Affymax's lead product candidate for the treatment of anemia, continues to progress as planned.
"Our partnership is u...
|
|
Feb 5, 2008
|
Affymax to Present at BIO CEO & Investor Conference
|
5.8 KB |
|
| |
PALO ALTO, Calif., Feb 05, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 10th Annual BIO CEO & Investor Conference on Wednesday, February 13, 2008, at 12:30 p.m. ET at the Waldorf-Astoria in New York City.
A live webcast of the pr...
|
|
Jan 25, 2008
|
Takeda Doses First Patient In A U.S. Phase 1 Study Of Hematide™ To Treat Chemotherapy Induced Anemia
|
8.7 KB |
|
| |
OSAKA, Japan (Jan-25) and PALO ALTO, Calif. (Jan-24), 2008 - Takeda Pharmaceutical Company Limited (TSE: 4502) and Affymax, Inc. (Nasdaq: AFFY) today announced that Takeda has dosed the first patient in the United States in a clinical trial of the investigational new drug, Hematide™, for the treatment of anemia in cancer patie...
|
|
Dec 10, 2007
|
Affymax Appoints Keith Leonard and Christi van Heek to its Board of Directors
|
8.1 KB |
|
| |
PALO ALTO, Calif., Dec 10, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Keith Leonard and Christi van Heek to the company's board of directors. Mr. Leonard has nearly 20 years of operations experience at biotechnology companies, including 13 years at Amgen, Inc. Ms. van Heek's 25 years in the healthcare and...
|
|
Dec 6, 2007
|
Affymax to Participate on Panel at RBC Capital Markets Healthcare Conference
|
5.9 KB |
|
| |
PALO ALTO, Calif., Dec 06, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul Cleveland, the company's executive vice president and chief financial officer, will participate on the Replacing the Mainstay with Newer and Better Agents panel at the RBC Capital Markets Healthcare Conference on Wednesday, December 12, 2007, at...
|
|
Nov 12, 2007
|
Affymax(R) Reports Third Quarter 2007 Financial Results
|
10.9 KB |
|
| |
PALO ALTO, Calif., Nov 12, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced financial results for the third quarter ended September 30, 2007. The net loss for the third quarter of 2007 was $12.7 million, compared to a net loss of $6.4 million for the third quarter of 2006. The net loss for the first nine months of 2007 was $29.1 ...
|
|
|
